DDInter1828 DDInter704
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Tolbutamide {u} (Compound) upregulates {v} (Gene) PLCB3
PLCB3 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Tolbutamide {u} (Compound) downregulates {v} (Gene) IFRD2
IFRD2 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Tolbutamide {u} (Compound) upregulates {v} (Gene) PDHX
PDHX {u} (Gene) is downregulated by {v} (Compound) Everolimus
Tolbutamide {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Everolimus
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Tolbutamide {u} (Compound) upregulates {v} (Gene) PLCB3
PLCB3 {u} (Gene) regulates {v} (Gene) GFOD1
GFOD1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Tolbutamide {u} (Compound) downregulates {v} (Gene) IFRD2
IFRD2 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Tolbutamide {u} (Compound) downregulates {v} (Gene) RPN1
RPN1 {u} (Gene) regulates {v} (Gene) MCOLN1
MCOLN1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Tolbutamide {u} (Compound) upregulates {v} (Gene) PDHX
PDHX {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Tolbutamide (Compound) upregulates PLCB3 (Gene) and PLCB3 (Gene) is upregulated by Everolimus (Compound)
Tolbutamide (Compound) downregulates IFRD2 (Gene) and IFRD2 (Gene) is downregulated by Everolimus (Compound)
Tolbutamide (Compound) upregulates PDHX (Gene) and PDHX (Gene) is downregulated by Everolimus (Compound)
Tolbutamide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Everolimus (Compound)
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Tolbutamide (Compound) upregulates PLCB3 (Gene) and PLCB3 (Gene) regulates GFOD1 (Gene) and GFOD1 (Gene) is upregulated by Everolimus (Compound)
Tolbutamide (Compound) downregulates IFRD2 (Gene) and IFRD2 (Gene) is downregulated by Temsirolimus (Compound) and Temsirolimus (Compound) resembles Everolimus (Compound)
Tolbutamide (Compound) downregulates RPN1 (Gene) and RPN1 (Gene) regulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Everolimus (Compound)
Tolbutamide (Compound) upregulates PDHX (Gene) and PDHX (Gene) is downregulated by Temsirolimus (Compound) and Temsirolimus (Compound) resembles Everolimus (Compound)